SCHEMBL2398147

SCHEMBL2398147

Cc1ccc(Cn2cnnc2-c2ccc3[nH]cnc3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCTL Q9NXS2 5/20 0.66
LMNA P02545 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
QPCT Q16769 4/20 0.40
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
HPGD P15428 2/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MMP13 P45452 1/20 0.36
BRD4 O60885 1/20 0.35
KCNH2 Q12809 1/20 0.34
IDO1 P14902 1/20 0.34
PDE10A Q9Y233 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2399845 0.91 QPCTL (0.63) QPCTLCYP11B1CYP11B2HTTSMN1; SMN2
SCHEMBL2398286 0.89 QPCTL (0.62) QPCTLQPCTPRMT5WDR77HPGD
SCHEMBL2397290 0.89 QPCTL (0.68) QPCTLCYP11B1CYP11B2QPCTPRMT5
SCHEMBL2398000 0.89 QPCTL (0.84) QPCTLQPCTBRD4
SCHEMBL2396993 0.88 QPCTL (0.69) QPCTLLMNAHTTSMN1; SMN2QPCT
SCHEMBL2395959 0.87 QPCTL (0.66) QPCTLLMNAHTTSMN1; SMN2QPCT
SCHEMBL2395188 0.87 QPCTL (0.59) QPCTLQPCTPRMT5WDR77BRD4
SCHEMBL2396775 0.85 QPCTL (0.57) QPCTLQPCTPRMT5WDR77
SCHEMBL2399121 0.85 QPCTL (0.85) QPCTLCYP11B1CYP11B2SMN1; SMN2QPCT
SCHEMBL2397148 0.85 QPCTL (0.71) QPCTLQPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP claimed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US claimed
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
WO-2011107530-A2 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224259-A1 NOVEL INHIBITORS QPCT, GLUL, GLS QPCTL 5/4885LMNA 3165/4885CYP11B1 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.